Pediatric Open Studies

Registry

COG-APEC14B1

Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study
https://clinicaltrials.gov/ct2/show/NCT02402244

Albert Kheradpour, MD

CNS

COG-ACNS0831

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
https://www.clinicaltrials.gov/ct2/show/NCT01096368

Albert Kheradpour, MD

COG-ACNS1422

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
https://clinicaltrials.gov/ct2/show/NCT02724579

Albert Kheradpour, MD

Oncoceutics-ONC018

Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas
https://clinicaltrials.gov/ct2/show/NCT03134131

Albert Kheradpour, MD

National Children’s Hospital-Head Start IV

Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma And Other Central Nervous System Embryonal Tumors. Clinical And Molecular Risk-Tailored Intensive And Compressed Induction Chemotherapy Followed By Consolidation With Randomization To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
https://clinicaltrials.gov/ct2/show/NCT02875314

Albert Kheradpour, MD

Germ Cell

COG-A031102

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
https://clinicaltrials.gov/ct2/show/NCT02375204

Albert Kheradpour, MD

COG-AGCT1531

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
https://clinicaltrials.gov/ct2/show/NCT03067181

Albert Kheradpour, MD

Hodgkin’s Lymphoma

COG-AHOD1331

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
https://clinicaltrials.gov/ct2/show/NCT02166463

Albert Kheradpour, MD

COG-AHOD1721

Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation
https://clinicaltrials.gov/ct2/show/NCT02927769

Albert Kheradpour, MD

Kidney

COG-AREN03B2

Renal Tumors Classification, Biology and Banking Study
https://clinicaltrials.gov/ct2/show/NCT00898365

Albert Kheradpour, MD

Leukemia

COG-AALL1131

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND #73789, NSC #606869) in the Very High Risk Stratum
https://clinicaltrials.gov/ct2/show/NCT01406756

Albert Kheradpour, MD

COG-AALL1331

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
h https://clinicaltrials.gov/ct2/show/NCT02101853

Albert Kheradpour, MD

COG-AALL1521

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02723994

Albert Kheradpour, MD

COG-AALL1621

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
https://clinicaltrials.gov/ct2/show/NCT02981628

Albert Kheradpour, MD

COG-AALL1631

International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
https://clinicaltrials.gov/ct2/show/NCT03007147

Albert Kheradpour, MD

COG-AAML1331

A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All Trans-Retinoic Acid
https://clinicaltrials.gov/ct2/show/NCT02339740

Albert Kheradpour, MD

COG-ACCL1333

A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase
https://clinicaltrials.gov/ct2/show/NCT02369653

Albert Kheradpour, MD

COG-ADVL1521

A Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03190915

Albert Kheradpour, MD

Lymphoma

COG-ANHL12P1

A Randomized Phase 2 Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)
https://clinicaltrials.gov/ct2/show/NCT01979536

Albert Kheradpour, MD

Multiple

COG-APEC1621

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Document
https://clinicaltrials.gov/ct2/show/NCT03233204

Albert Kheradpour, MD

Pfizer-B0661037

A Randomized, Open-Label, Active controlled, Safety and Descriptive Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of a Venous Thromboembolic Event
https://clinicaltrials.gov/ct2/show/NCT02464969

Albert Kheradpour, MD

Neuroblastoma

COG-ANBL00B1

Neuroblastoma Biology Studies
https://clinicaltrials.gov/ct2/show/NCT00904241

Albert Kheradpour, MD

COG-ANBL1232

Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT02176967

Albert Kheradpour, MD

COG-ANBL1531

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
https://clinicaltrials.gov/ct2/show/NCT03126916

Albert Kheradpour, MD

Rhabdomyosarcoma

COG-ARST1431

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
https://clinicaltrials.gov/ct2/show/NCT02567435

Albert Kheradpour, MD

Solid Tumors

COG-ADVL1622

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
https://clinicaltrials.gov/ct2/show/NCT02867592

Albert Kheradpour, MD

COG-ADVL1722

A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)
https://clinicaltrials.gov/ct2/show/NCT03441360

Albert Kheradpour, MD

COG-AEWS1221

Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
https://clinicaltrials.gov/ct2/show/NCT02306161

Albert Kheradpour, MD

COG-ANHL1522

A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
https://clinicaltrials.gov/ct2/show/NCT02900976

Albert Kheradpour, MD

COG-ADVL1711

A Phase 1/2 Study of Lenvatinib in combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS tumors
https://clinicaltrials.gov/ct2/show/NCT03245151

Albert Kheradpour, MD

Stem Cell Transplant

NMDP-10-CBA

A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
https://www.clinicaltrials.gov/ct2/show/NCT01351545

Rishikesh Chavan, MD

NMDP-RESEARCH DATABASE

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
https://www.clinicaltrials.gov/ct2/show/NCT00495300

Rishikesh Chavan, MD

NMDP-SAMPLE REPOSITORY

A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)
https://www.clinicaltrials.gov/ct2/show/NCT00495300

Rishikesh Chavan, MD

Keyword Search

Services & Treatments

Provider Search

Location Search